First In Human Study Evaluating the Safety and Performance of the "LapBox" Containment System for Laparoscopic Tissue Morcellation

Laparoscopic Surgical Procedure Clinical Trial

Official title:

First In Human Study Evaluating the Safety and Performance of the "LapBox" Containment System for Laparoscopic Tissue Morcellation

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04231812
• Other study ID #: ARK-001
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 25, 2020
• Est. completion date: May 1, 2020

Study information

• Verified date: January 2020
• Source: ARKSurgical
• Contact: Stav Tori
• Phone: 972523594441
• Email: stav[@]ark-surgical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study to assess the safety, and performance of the LapBox in patients in terms of duration of deployment, organ insertion into the "LapBox" bag, ease of use, success of containment and performance.

Description:

The LapBox is intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy Ten (10) adult female patients, scheduled for the laparoscopic gynecological procedure, with up to 700gr mass to be removed and with no suspicion of malignancy.

Patients scheduled for elective laparoscopic hysterectomy, myomectomy or removal of an adnexal mass where either manual morcellation or power morcellation is needed for tissue will be enrolled. Each patient will be required to participate in 3 visits:

Visit 1: Screening and Enrollment, as part of the pre-operative visit and confirmation of compliance. Such a visit can be more than 1 day.

Visit 2: Laparoscopic organ removal procedure- morcellation utilizing LapBox containment system.

Visit 3:up appointment up to 7 weeks (7 days) post-procedure.

During visit 2 (laparoscopic organ removal procedure), the following steps will be performed:

• Following tissue harvest and prior to morcellation, a peritoneal wash sample will be obtained for a cytology evaluation.

• The LapBox will then be inserted to the patient abdomen through the abdominal wall and deployed.

• The harvested tissue will be inserted into the LapBox using standard technique.

• The LapBox opening will be extracted outside the abdomen.

• Depending on the type of morcellation (power or mechanical), the incision may be extended as needed.

• The appropriate type of port will be placed.

Power morcellation:

• The morcellator will be inserted.

• The laparoscope will be placed inside the bag and provide visualization of the procedure. Alternatively, direct visualization may be utilized.

• The morcellator will be operated in a standardized fashion. Manual morcellation will be performed as per standard practice.

• The LapBox will be removed through the abdominal opening. A second peritoneal wash sample will be obtained for a cytology evaluation in order to compare pre and post morcellation findings.

Following the procedure, tissue weight will be recorded, and leakage testing will be performed on used devices.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: May 1, 2020
• Est. primary completion date: May 1, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Female patients indicated for elective surgery requiring laparoscopic hysterectomy, myomectomy where either manual morcellation or power morcellation is needed for tissue removal at which a morcellator for cutting and extraction of tissue is required.

2. Pre- menopausal woman patient age 18-50 years

3. Mass measured with diameter up to 10 cm to be removed

4. Normal Pap test result within the last 24 months prior to enrollment

5. Normal and /or Non-Clinically Significant as per investigator discretion CBC and Blood chemistry test within at least 6 months prior to surgery.

6. Signed an informed consent

Exclusion Criteria:

1. Emergency cases

2. Abdominal wall thickness is greater than 10 cm according to US measurements.

3. Patient requires procedure involving the ovaries (e.g., Oophorectomy, Salpingo)

4. Patient is defined as a "high risk" patient for developing cancer (per standard assessment, including but not limited to imaging)

5. Suspicion of malignant or pre-malignant tissue according to preoperative assessment including US exam within 30 days prior to surgery

6. Known or suspected gynecologic malignancy within the past five years

7. Pacemaker, internal defibrillator/cardio converter

8. Previous extensive pelvic surgery or any other medical procedure which in the investigator's judgment contraindicates the patient's participation

9. Contraindications to anesthesia or abdominal surgery. ASA score above 3

10. Concurrent participation in any other clinical study

11. Active infection at the time of the procedure.

12. BMI<20 or BMI>40

13. Known history or presence of any medical disorder, which in the investigator's judgment contraindicates the patient's participation (e.g., Known and documented active liver disease, renal failure, cognitive disorder, cardiopulmonary disease, impaired coagulation parameters, etc.)

Related Conditions & MeSH terms

• Laparoscopic Surgical Procedure

Intervention

Device:
• Laparoscopic Tissue Morcellation working space (bag)
The "LapBox" is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
ARKSurgical

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Device Related Adverse Events Occurrence	Occurrence of device use related adverse events as documented and reported, under DSMB review	through study procedure, up to 10 weeks from procedure
Primary	Device Performance and Integrity	Leak testing will be performed following the each procedure to confirm device integrity.; Used device will be filled with color fluid to provide clear identification of possible leakage. Test will performed by Investigator delegated study team member and results will be documented in CRF.	following completion of procedure and study device use (1 day)
Secondary	Device performance	Comparison of the presence of cancerous cells pre and post morcellation via peritoneal wash sample cytology	up to 10 weeks following the procedure
Secondary	Device Performance (usability)	Ease of use of the device (usability evaluation via questionnaire).	following completion of procedure and study devise use (1 day)
Secondary	Device Performance	Intra- or post-operative complications, Adverse Events and Device Related Adverse Events	through study procedure, up to 10 weeks from procedure
Secondary	Device Performance	Procedure time	following completion of procedure and study device use (1 day)
Secondary	Device Performance	Hospitalization length	up to 10 weeks following the procedure
Secondary	Device Performance	Specimen (removed tissue) weight collection	following completion of procedure and study devise use (1 day)